CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 25878332.
- Also identified by DOI 10.1158/1078-0432.CCR-14-3190.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
CD38 is a type II transmembrane glycoprotein that is highly expressed in multiple myeloma and is a promising target for immunotherapy. Daratumumab is a human monoclonal antibody that has potent anti-multiple myeloma activity both as monotherapy and in combination with other multiple myeloma treatments, and has breakthrough designation on this basis.
Medical subject headings
- ADP-ribosyl Cyclase 1
- Bortezomib
- Multiple Myeloma
- Thalidomide